purpura/癲癇性発作

meningitis is a notifiable disease in many countries, the exact incidence rate is unknown. In 2013 meningitis resulted in 303,000 deaths - down from 464,000 deaths in 1990. In 2010 it was estimated that meningitis resulted in 420,000 deaths, excluding cryptococcal meningitis. Bacterial meningitis

Specific Aim 1: Establish a cCMV testing protocol and demonstrate that this protocol is successful at identifying infants with cCMV who present with hearing abnormality as the first sign of infection. Specific Aim 2: Demonstrate that a majority of infants who test positive for cCMV at the time of

Epilepsy and cognitive dysfunction Recent investigations suggest that more than 60% of patients with epilepsy suffer cognitive impairment, such as memory, attentional and executive dysfunction (Elger et al., 2004, Lin et al., 2012). The severity and profile of cognitive impairment are heterogeneous

Transcranial direct current stimulation (tDCS) is a powerful technique to modulate brain activity: TDCS is based on the application of a weak direct current to the scalp that flows between two relatively large electrodes—anode and cathode. During tDCS, low amplitude (1-2 mA), constant currents are

1 Introduction This document is a protocol for a human research study. This study is to be conducted in accordance with US government research regulations, and applicable international standards of Good Clinical Practice, and institutional research policies and procedures. 1.1 Background Focal

Japanese encephalitis (JE) is the most important epidemic encephalitis worldwide, causing approximately 35-50,000 cases and 10-15,000 deaths annually. Half of the survivors have severe neuropsychiatric sequelae, posing a large socio-economic burden on communities that can ill afford it. JE virus

This is an observational study, vaccines administration and data that is collected is only as part of routine clinical care. Vaccinated subjects are not actively recruited. Events of interest: Seizure, Aseptic meningitis, Bell's Palsy, Multiple Sclerosis, Guillain-Barre Syndrome, Acute disseminated

Participants were randomized to either receive 3 injections of CYD dengue vaccine or a placebo at 0, 6, and 12 months. A subset of participants from each country were also evaluated for reactogenicity and immunogenicity. Participants who consented to participate in the SEP were actively followed for

Participants (both cohort 1 and 2) received 3 injections of CYD dengue vaccine. Participants (Cohort 1) received rabies vaccine at Month 0 and placebo at 6 and 12 months. Participants (cohort 2) received placebo at 0, 6, and 12 months. Dengue cases were collected for assessment of efficacy during